Apatinib, a heavyweight new drug of Hengrui medicine, is expected to be approved within one month
-
Last Update: 2014-09-29
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
According to the public data, apatinib belongs to class 1 chemical medicine It is a me better drug modified on the basis of vandetanib and PTK787, which is suitable for cancer patients after the failure of other treatment methods The preclinical research shows that its antitumor effect is better than that of PTK787 According to the information on CFDA website, apatinib is a major special drug At present, there are no domestic enterprises with the production approval documents of apatinib It is worth mentioning that the indication of apatinib for production is gastric cancer, and the indication of liver cancer is undergoing clinical trials at the same time Guangfa Securities research report pointed out that the annual incidence of gastric cancer in China is more than 500000, and the annual incidence of liver cancer is more than 400000 At present, the monthly average cost of TiNi patients is more than 10000 yuan, and the market space for gastric cancer and liver cancer indications is expected to reach 1 billion yuan.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
